| dc.contributor.author | Queiro Silva, Rubén | |
| dc.date.accessioned | 2022-04-22T11:14:35Z | |
| dc.date.available | 2022-04-22T11:14:35Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | Expert opinion on biological therapy, 21(12), p. 1539-1541 (2021); doi:10.1080/14712598.2022.1998448 | |
| dc.identifier.issn | 1471-2598 | |
| dc.identifier.uri | http://hdl.handle.net/10651/63009 | |
| dc.format.extent | p. 1539-1541 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Expert opinion on biological therapy | |
| dc.rights | © 2021 Informa UK Limited, trading as Taylor & Francis Group | |
| dc.source | Scopus | |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118423396&doi=10.1080%2f14712598.2022.1998448&partnerID=40&md5=d693313cae2a4545aba65427474ebfb5 | |
| dc.title | Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine? | |
| dc.type | journal article | |
| dc.identifier.doi | 10.1080/14712598.2022.1998448 | |
| dc.relation.publisherversion | http://dx.doi.org/10.1080/14712598.2022.1998448 | |
